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Background and purpose: Until now, stroke and transient ischemic attack (TIA) have 
been clinically based terms which describe the presence and duration of characteristic 
neurological deficits attributable to intrinsic disorders of particular arteries supplying the 
brain, retina, or (sometimes) the spinal cord. Further, infarction has been pathologically 
defined as death of neural tissue due to reduced blood supply. Recently, it has been 
proposed we shift to definitions of stroke and TIA determined by neuroimaging results 
alone and that neuroimaging findings be equated with infarction.
Methods: We examined the scientific validity and clinical implications of these proposals 
using the existing published literature and our own experience in research and clinical 
practice.
results: We found that the proposals to change to imaging-dominant definitions, as 
published, are ambiguous and inconsistent. Therefore, they cannot provide the stan-
dardization required in research or its application in clinical practice. Further, we found 
that the proposals are scientifically incorrect because neuroimaging findings do not 
always correlate with the clinical status or the presence of infarction. In addition, we 
found that attempts to use the proposals are disrupting research, are otherwise clinically 
unhelpful and do not solve the problems they were proposed to solve.
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Conclusion: We advise that the proposals must not be accepted. In particular, we 
explain why the clinical focus of the definitions of stroke and TIA should be retained 
with continued sub-classification of these syndromes depending neuroimaging results 
(with or without other information) and that infarction should remain a pathological 
term. We outline ways the established clinically based definitions of stroke and TIA, 
and use of them, may be improved to encourage better patient outcomes in the 
modern era.
Keywords: stroke, transient ischaemic attack, infarction, asymptomatic carotid stenosis, public health practice
introdUCtion
It is vital that everyone, including patients, carers, clinicians, 
researchers, policy makers, health-care funders, and the general 
public, know what is meant by “stroke” because everyone has 
a role to play in optimizing action to reduce its impact. Stroke 
imposes huge socioeconomic burdens, being persistently among 
the top three causes of disability and premature mortality world-
wide (1, 2). Further, stroke is highly preventable and effective 
hyperacute therapies are now available (3–6). As explained in 
this report, stroke has been a clinically based diagnosis, describ-
ing the nature and duration of deficits, with sub-categorization 
according to neuroimaging results. This remains appropriate 
(despite advances in neuroimaging and therapies) because the 
clinical status matters most to patients. Further, the clinical 
status (or anticipation of it) is the reason for, and target of, any 
treatment. The clinical status must be weighed up against the 
risks of treatment and has been the primary outcome measure 
in studies of prognosis and therapy. As explained below, there 
have been proposals to change the definitions of stroke, tran-
sient ischemic attack (TIA), and infarction to ones dominated by 
neuroimaging results. In this report, we present these proposals 
and the reasons given for them. Further, we use our own experi-
ence in clinical practice and research to demonstrate how these 
proposals are problematic. Finally, we hypothesize regarding 
how the existing clinically based definitions of stroke and TIA 
may be optimized in the modern era.
tHe MeaninG oF stroKe, tia,  
and inFarCtion
the established Clinically Based 
definitions
For several decades, the meaning of “stroke” (in scientific and lay 
literature) has most often been consistent with the 1980 World 
Health Organization (WHO) definition as “rapidly developed 
clinical signs of focal (or global) disturbance of cerebral func-
tion, lasting more than 24 h or leading to death, with no apparent 
cause other than of vascular origin” (7). This definition describes 
a clinical syndrome. It includes no details regarding vascular 
mechanism because its utility lies in optimizing the identification 
of all deficits caused by cerebral ischemia (reduced blood supply) 
or hemorrhage. Both of these fundamental conditions produce 
similar clinical features and require urgent medical attention. 
The stroke mechanism is determined, as clearly as possible, 
once such attention is provided. Of note, “global” disturbance 
of cerebral function referred only to patients with subarachnoid 
hemorrhage and without “focal” neurological deficits (7) and is 
often omitted in practice. However, although features suggesting 
global cerebral disturbance (such as impaired or loss of con-
sciousness) are not commonly associated with focal, intrinsic 
cerebrovascular ischemia, they may occur (8–10), just as they 
can with subarachnoid hemorrhage (11).
Stroke has been distinguished from TIA which most often has 
been interpreted as the 1975 National Institutes of Health (NIH) 
definition as “episodes of temporary and focal cerebral (includ-
ing retinal) dysfunction of vascular origin, rapid in onset which 
commonly last 2–15 min but occasionally up to a day (24 h)” 
where “resolution is swift and leaves no permanent [clinical] 
neurologic deficit” (12). This definition was formulated recog-
nizing that duration of clinical features associated with untreated 
cerebrovascular compromise follows a spectrum. Most deficits 
which resolve spontaneously within 24 h, do so within the first 
minutes or hours (13–15). Using a standard time-point to dif-
ferentiate short from long-term deficits provides a “common” 
basis for “collecting” information about the large population 
with clinical deficits that resolve quickly with no detectable 
residuum, whether or not hyperacute treatment is used (12, 16, 
17). As discussed later, strengths of 24-h time-point include that 
it is relatively easily measured, it has been the main standard 
to date and it can be used as an important outcome measure of 
hyperacute treatment or prevention strategies.
The WHO and NIH definitions of stroke and TIA are concise 
and dependent only on recognition of fundamental clinical fea-
tures. Therefore, they are easily accessible to the public and pro-
fessionals anywhere in the world following some relatively basic 
education. They are completely amendable to sub-classification 
using additional information, including neuroimaging results. 
They facilitate an orderly framework for proceeding from clinical 
stage to most likely mechanism and best management (12). As 
discussed later, improvement can be made by providing detail 
about typical clinical presentations and specifying the inclusion, 
or not, of stroke and TIA of the retina and/or spinal cord or 
syndromes due to arterial and/or venous infarction. However, 
these core definitions have predominated in the past decades of 
research and communication of research findings. Consequently, 
they hold the strongest overall value for the identification, 
management, prognostication, and prevention of acute cerebro-
vascular emergencies.
3Abbott et al. Definitions of Stroke, TIA, and Infarction
Frontiers in Neurology | www.frontiersin.org October 2017 | Volume 8 | Article 537
proposals to Change to imaging-
dominant definitions
Changes to these established definitions have been proposed by 
representatives of the American Heart and Stroke Associations 
(AHA/ASA) and others in three publications (18–20). Although 
suggestions made differ, there is a common proposal to shift from 
clinically based definitions of stroke and TIA (describing the 
presence and duration of characteristic neurological deficits) to 
definitions according to neuroimaging alone. A further proposal 
is that imaging findings be equated with infarction. However, to 
date “infarction” has been a pathological term used to describe 
tissue that has lost its blood supply for long enough to undergo 
ischemic necrosis (death) with characteristic macroscopic and 
microscopic findings (21). Infarction can only be accurately 
identified using histopathologic techniques.
As explained in below, we have observed that attempts to use 
the AHA/ASA proposed new definitions are causing confusion 
and chaos. This is not surprising given that the proposed new 
“definitions” are ambiguous, scientifically incorrect, research 
disrupting, otherwise clinically unhelpful and do not solve the 
problems they were proposed to solve. The value of brain imag-
ing in the management of patients with clinical features of acute, 
focal central-neurovascular compromise is not being questioned 
here. It is the proposal to change from clinically based to imaging-
dominant definitions that is problematic.
tHe proposaLs are aMBiGUoUs
2002 proposals
The proposed new definitions of stroke and TIA fail because 
of ambiguity (18–20). For example, it was proposed in 2002 
that TIA now be defined as “a brief [not defined] episode of 
neurologic dysfunction caused by focal brain or retinal ischemia 
with clinical symptoms typically lasting less than one hour and 
without evidence of acute infarction [not defined]. The corollary 
is that persistent [not defined] clinical signs or characteristic 
imaging abnormalities [not defined] define infarction- that 
is stroke.” (18) This text contains no valid definitions because 
the duration of symptoms and what constitutes infarction 
(or, more appropriately, imaging evidence of infarction) were 
not specified.
2009 proposals
The 2009 suggestion by Easton et al. added to the ambiguity by 
removing more detail: “TIA: a transient [not defined] episode 
of neurological dysfunction caused by focal brain, spinal cord 
or retinal ischemia without acute infarction [not defined].” 
(19) Further, it was proposed that ischemic stroke be defined 
as “infarction [not defined] of the central nervous system” 
whereas TIA be defined as “symptomatic ischemia [not defined] 
without infarction [not defined].” Equivocacy was amplified by 
inconsistency. Initially it was proposed that that ischemic stroke 
requires the presence of “infarction” and later, that some ischemic 
strokes will be rendered “only on the basis of clinical features.” 
It was also proposed, perhaps clarifying the 2002 proposal, that 
“ischemic strokes” refer to “symptomatic or silent” brain imaging 
abnormalities (19). The place of primary cerebral hemorrhage in 
the definition of stroke was not addressed in either publication.
2013 proposals
In the third publication (2013) the suggested new definitions dif-
fered again with shifts back to a clinical basis and acknowledgment 
of the pathological dimension of cerebrovascular disease (20). 
However, as in 2002 and 2009, the proposed new 2013 definition of 
infarction remains unspecified: “infarction is brain, spinal cord or 
retinal cell death attributable to ischemia based on patholological 
[not defined], imaging [not defined] or other objective evidence 
[not defined] and/or clinical evidence [not defined].” There again 
was inconsistency with a later proposal that central nervous 
system infarction be defined using an explicit “vascular distribu-
tion” and a “≥24 h” duration for “clinical evidence.” Further, a 405 
word stroke definition was proposed, too long for everyday use. 
These AHA/ASA proposals cannot provide standardization, only 
confusion. This is reason enough that these proposals should not 
be accepted.
tHe proposaLs are sCientiFiCaLLy 
inCorreCt
The fundamental AHA/ASA proposal is that brain imaging must 
be used, or may be used alone, to diagnose stroke (the patient’s 
clinical deficits) and infarction (ischemic death of central nerv-
ous system tissue). Both aspects are scientifically incorrect. Brain 
imaging findings do not always correlate with clinical deficits or 
infarction. As mentioned, the timing and nature of brain imag-
ing proposed to “identify” stroke, TIA, and infarction were not 
specified (18–20). However, early echo-planar diffusion-weighted 
(DWI) magnetic resonance imaging (MRI) is especially impli-
cated because of its superiority in detecting “positive” evidence of 
ischemia (rather than simply excluding alternative pathologies) 
compared to other MRI sequences (22–24) and, in particular, 
compared to computed tomography (CT).
Limited sensitivity of Cerebral 
neuroimaging
Reported sensitivities of non-contrast CT brain performed 
0–6 h after clinical onset in detecting “positive” evidence of brain 
ischemia (such as hypo-attenuation, loss of white/gray matter 
differentiation, focal cortical swelling, hyper-dense arterial signs 
and/or compression of adjacent structures) vary from 12 to 66% 
(25–27). This can be improved somewhat by using contrast and 
CT perfusion (CTP) imaging (28). However, CTP is limited 
in detecting change indicative of cerebral ischemia, including 
infarction, and is susceptible to larger measurement errors than 
DWI (29, 30). “Positive” DWI evidence of acute brain ischemia 
may sometimes be seen minutes after arterial compromise 
as hyperintensity (31, 32). From animal models, early DWI 
hyperintensity is consistent with increased restriction of extra 
cellular water diffusion as water enters cells due to impaired 
membrane homeostasis (cell swelling or cytotoxic edema) 
(31, 33–35). However, as well recognized, all brain imaging 
(including DWI) is limited in characterizing ischemic tissue and 
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stroke syndromes (20, 29, 36). Correlation of clinical features, 
imaging, and biological sampling (including, on occasion, brain 
tissue) is essential for maximizing diagnostic accuracy because 
all three dimensions are limited individually and provide addi-
tive value (37–42).
For example, reported DWI sensitivities (with 1.5–3 T field 
strength) for showing “positive” evidence of corresponding 
brain ischemia in patients imaged 0–6  h after clinical onset 
vary from 73 to 100% (25, 27, 42–44) and from 0 to 100% if 
imaged 0–90 or >14 days after clinical onset (including personal 
communication from Alejandro Brunser) (22, 23, 26, 27, 39, 41, 
45–51). In some of these studies, imperfect sensitivity (0–100%) 
related specifically to patients with ischemic stroke defined by 
typical clinical deficits lasting >24 h with/without correspond-
ing lesions on repeat DWI, T2, or fluid attenuation inversion 
recovery (FLAIR) MRI performed >24 h after clinical onset (23, 
39, 45, 46, 48, 51). Further, the smallest infarcts are sometimes 
below the structural resolution (approximately 1  mm3) of 
1.5–3.0 T MRI and although the resolution of 7 T MRI is better, 
it is not perfect (36, 52–54).
Diffusion-weighted negativity is more likely with brief deficits 
(48, 55), imaging performed within 3–72 h (27, 46, 50) or after 
2–3  weeks of clinical onset (39, 45), with acute on chronic 
infarction (47), less severe clinical features (for instance, NIHSS 
score  <  4) (27, 39, 42), small areas of imaging abnormality 
(<5–10  mm) (46, 50), female gender (39), younger age (39), 
location in the posterior circulation (23, 27, 42, 46, 47, 49, 50), 
strokes attributable to small vessel disease (42, 47, 49), and less 
experienced image interpretors (25). DWI negativity is also 
more likely with increasing number of such predictors (27). 
Sensitivity may be improved by additional MR perfusion imaging 
(34, 42, 56). However, as commonly implemented, this requires 
gadolinium-based contrast and is limited by other factors, includ-
ing unreliable result interpretation (29, 57). Stroke patients with 
corresponding positive DWI evidence of brain ischemia are 
more likely to have recurrent DWI “lesions” than stroke patients 
without corresponding positive DWI evidence of brain ischemia 
(51). This may indicate an individual susceptibility to developing 
DWI abnormalities (51).
If DWI is negative, other MRI sequences (such as T2 or 
FLAIR) may show signs of corresponding brain ischemia 
(including focal hyperintensity), particularly when patients are 
imaged sub-acutely (up to 8 weeks after clinical onset) (37, 39, 
40, 46). Conversely, with subacute presentations, DWI may be 
“positive” when T2 is negative, especially with smaller lesions 
(24). However, MRI (using DWI and/or T2 and/or FLAIR and/
or T1) performed 0–27 days from clinical onset has shown no 
evidence of corresponding ischemia in 3–29% of patients with 
typical stroke deficits lasting >24 h (23, 39, 46, 51).
Limited specificity of Cerebral 
neuroimaging
In addition, MRI-DWI has imperfect specificity for identifying 
areas of acute cerebral ischemia. Non-stroke conditions, includ-
ing hypoglycemia, viral encephalitis, abscesses, cysts, old infarcts, 
multiple sclerosis, trauma, migraine, transient global amnesia, 
mitochondrial disorders, prion disease, methanol poisoning, 
cellular tumors (such as lymphoma), seizures, and other condi-
tions may produce DWI hyperintensity (38, 41, 47, 51, 58–69). 
While the distribution of hyperintensity usually differs somewhat 
with different pathologies, overlap occurs (38, 66). For, example 
hypoglycemia can exactly mimic focal ischemia on all sequences, 
including DWI (66). Reported DWI specificities in detecting 
evidence of corresponding brain ischemia in patients imaged 
0–12 h from clinical onset vary from 75 to 95% (27, 42, 47) and 
from 96 to 100% in patients imaged 0–8 days from clinical onset 
(25, 27, 41, 47).
Further, DWI is not reliable for estimating “lesion” age. DWI 
can be “positive” for up to several weeks or sometimes many 
months after acute ischemic stroke symptom onset before nor-
malization, with notable lack of predictability (24, 37, 70, 71). 
DWI lesions may be hyper-intense in the subacute phase due 
to increased T2 signal (T2 shine through). Apparent diffusion 
coefficient (ADC) values can help interpret DWI because they 
do not have a T2 component and are typically reduced, produc-
ing hypodense images, in the first 7–10  days of clinical onset. 
They then typically become iso-intense (pseudo-normalization) 
and then hyper-intense compared to normal brain (22, 70, 72). 
However, ADC values may take hours (73) or many months (37) 
to normalize with notable inter-individual variation. No ADC 
values (even if severely reduced) reliably define infarction, even 
though trends have been observed (29, 35, 74, 75). Further, ADC 
values can be reduced in many conditions other than acute brain 
ischemia (67).
There is other evidence that MRI (including DWI) does not 
just detect infarction. It may also detect “penumbra” (salvageable 
tissue) as evidenced by patients with acute deficits and correspond-
ing DWI changes who make a full spontaneous clinical recovery, 
within minutes to days of onset (56, 74, 76–78). In addition, DWI 
abnormalities can completely vanish and leave no signal abnor-
malities on repeat DWI, T1, T2, and/or FLAIR imaging several 
days, weeks or months later, whether or not deficits resolve spon-
taneously (23, 74, 76, 79–81). Further, penumbra or infarcted 
tissue may be missed by initial MRI because “infarct” growth 
(as defined using MRI) may occur in about 50% of patients without 
diffusion/perfusion imaging mismatch (29, 82). In addition, DWI 
lesions may first appear only days after isolated perfusion deficits 
which are seen within 24 h of the clinical onset of suspected stroke 
or TIA (83). These populations require further study.
Studies of DWI reversal after thrombolysis have usually focused 
on the first 1–7 days after clinical onset, demonstrating some or 
complete “early sustained” DWI reversal over sequential scans in 
0–50% of patients or “DWI lesions” (79, 84–87). To account for 
possible confounding effects of DWI “pseudo-normalization” in 
the first 7–10 days, partial late and sustained DWI reversal has 
also been described involving an average of 20% of the initial 
DWI hyperintensity volume in 7% of patients 30 or 90 days after 
thrombolysis (44). DWI reversal after thrombolysis (by varying 
definitions) is more likely, or more noticeable, with absence 
of baseline perfusion deficits, thrombolysis <3  h, evidence of 
reperfusion or small lesions (44, 85, 88, 89). In some studies, DWI 
reversal within a week of clinical onset was associated with better 
clinical outcomes (79, 86–90).
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Limited sensitivity and specificity of 
spinal Cord neuroimaging
Research regarding spinal cord stroke or infarction and imaging 
is less common than for cerebrovascular disease and challenged 
by perceived rarity of spinal cord stroke, variable clinical mani-
festations, complex spinal arterial supply, technical challenges, 
and overall limitations in differentiating ischemia from other 
pathological processes (91, 92). Sensitivities of 67–100% have 
been reported for initial plus/minus repeat T2 MRI in detecting 
evidence of ischemic injury in patients with sudden spinal cord 
deficits of no other apparent cause (91, 93, 94). As with cerebro-
vascular disease, negative T2 is more likely with less severe defi-
cits or hyperacute imaging (93, 94). Spinal DWI is an emerging 
application which appears to improve early diagnostic sensitivity 
(92). Pathologically diagnosed lacunar type cord infarcts are 
common in patients dying of cerebrovascular disease, indicating 
scope for improved case ascertainment (95).
the important role of the 
neuropathologist
Finally, the 2002 and 2009 AHA/ASA proposals, in particular, 
abolish the role of the pathologist in stroke medicine. Brain 
tissue sampling carries risk and is not usually required to opti-
mize outcomes (38). However, occasionally a biopsy is the only 
mechanism for a correct diagnosis when the cause of a patient’s 
neurological deficit is unclear or atypical from the clinical and 
imaging information (38). Maintaining the pathological defini-
tion of infarction, the clinical definition of stroke and TIA and 
acknowledging the additive information from imaging recog-
nizes that imaging does not always accurately identify ischemia 
or infarction and that not all ischemic events are symptomatic or 
produce specific clinical or imaging features (36, 52, 54, 96, 97).
Brain images (including DWI, ADC and perfusion measure-
ments) in patients with stroke symptoms are only snap shots of a 
complex dynamic process. Although helpful with other informa-
tion, they alone are not fail-safe diagnostic markers of clinical 
status, infarction, “lesion core” or tissue at risk (29, 34, 57, 73, 
75, 98). The AHA/ASA proposals to use imaging to replace clini-
cal and pathological information are scientifically incorrect and 
confuse existing, purposeful terminology.
tHe proposaLs are researCH 
disrUptinG
problems Making Measurements  
and Comparisons
Research is about discovering new knowledge which is applied 
in clinical practice to improve patient outcomes. New knowledge 
discovery and its application require standardization of terminol-
ogy and concepts, which is removed by the AHA/ASA proposed 
definitions. Further, over-reliance on a test (such as DWI) which 
is highly variable with respect to availability, acquisition methods 
and interpretation is likely to reduce diagnostic accuracy (99). 
Stroke and TIA incidence and prevalence measurements will 
artificially change in proportion to the use of MRI and attempted 
use of the proposed definitions (99–101) and most likely in ways 
that are difficult or impossible to decipher depending on when 
and how MRI is used and to the extent research methods are 
described. The proposed shift to an imaging-dominant diagnostic 
approach will also artificially change outcome measurements. 
For instance, classifying clinical deficits lasting less than 24 h and 
accompanied by a DWI lesion as stroke would increase the pro-
portion of patients with good outcomes, according to the avail-
ability of neuroimaging and not through any health-care change. 
Countries with good access to MRI would likely see “improved” 
stroke outcomes compared to those without.
particular problems with Low rates  
and differentiating transient events  
with an example regarding stroke  
risk associated With asymptomatic 
Carotid stenosis
The AHA/ASA focus on imaging is causing confusion in dif-
ferentiating rates of extremely transient neurological deficits 
compared to long-term and permanent deficits caused by 
ischemia. This is particularly problematic in  situations where 
event rates are low and the principal objective is to prevent 
long-term neurological deficits, as with carotid procedures. For 
example, an attempt to use an AHA/ASA imaging-dominant 
“definitions” caused confusion and disruption while updating a 
2009 meta-analysis (3) of temporal change in the average annual 
ipsilateral stroke rate in patients with 50–99% asymptomatic 
carotid stenosis given medical (non-procedural) treatment 
alone (102). The original 2009 methods were repeated with 
inclusion of studies published from January 2009 to December 
2013 and identified using all PubMed listings with “carotid” in 
the title (8,480 listed after duplicate removal).
Five new measurements of average annual ipsilateral stroke 
rate from five apparently eligible studies were identified, see 
Table 1 (103–107). Two of these included a major update of stud-
ies included in the 2009 meta-analysis (105, 107). Only the most 
recent data were used in this meta-analysis update (105, 107). 
Two others were identified which were otherwise eligible except 
that they included a minority of patients (≤18%) with remote 
ipsilateral stroke or TIA (>18–24 months prior to recruitment) 
(17, 108). Analyses were made with and without including these 
two studies. As before, temporal changes in ipsilateral stroke 
rate were sought using ordinary least squares linear regression 
analysis, weighted according to sample sizes, using the new and 
previously identified studies (3).
With respect to change in the average annual ipsilateral stroke 
rate over time, there was a notable outlier with a statistically 
significant, approximately five times higher stroke rate compared 
to most other studies also published around 2010, see Figure 1 
(106). The reason was the use of proposed new stroke and TIA 
definitions from Easton et al. (19) (personal communication with 
Mauro Silvestrini). As mentioned, these proposed definitions 
were ambiguous. However, in the study by Silvestrini et  al., it 
meant that stroke was defined as “focal events (including tran-
sient) in which neuroimaging [MRI or CT] identified an ischemic 
lesion.” No “imaging-negative” deficits were noted. Therefore, the 
taBLe 1 | Average Annual Ipsilateral “Stroke” Rates in studies considered for the 2013 updated meta-analysis of patients with moderate–severe (≥50%) asymptomatic 
carotid stenosis given medical treatment alone.a,b
reference sample size % stenosis Follow-up (years) ipsilateral stroke rate included in Figure 1?
Gronholdt et al. (103) 111 ≥50 by US 4.4 mean 3.1 Yes
Marquardt et al. (104) 101 ≥50 by US or MRI 3 mean 0.3 Yes
Markus et al. (17) 477 ≥70 by US 2 for all patients 0.6 Yesc
Nicolaides et al. (105) 923 70–99% by US 4 mean 1.5 Yes
Silvestrini et al. (106) 162 60–99 by US 2.8 mean 2.9 No
Madani et al. (108) 253 ≥60 by US 3 for all patients 0.7 Yesc
den Hartog et al. (107) 293 50–99 by US 6.2 mean 0.3 Yes
aAll ipsilateral stroke rates were calculated using raw data and only the first ipsilateral stroke/patient. Further, patients with a first ipsilateral stroke and a prior ipsilateral transient 
ischemic attack (TIA) during follow-up were excluded when this distinction was possible. US, ultrasound; MRI, magnetic resonance imaging.
bDefinitions of stroke and TIA were clinically based except in the study by Silvestrini et al. which was imaging-dominant (106). Definitions of stroke in all other studies also included 
a 24-h differentiation from TIA (personal communication from Doctors Hugh Markus and Gert deBorst), except in the earliest study by Johnson et al. in which the time distinction 
between TIA and stroke was not defined (109).
cDid not meet the meta-analysis inclusion criteria for minor reasons (see text and Figure 1). Analyses were performed with and without the results of these two studies.
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“stroke” definition used in that study (and the follow-up paper) 
(110) was consistent with what others had called “stroke or TIA.” 
The results from Silvestrini et  al. had to be removed from this 
analysis to avoid artificial over-estimation of stroke risk using 
medical treatment alone. Meanwhile, all other studies in Figure 1 
used a clinically based definition of stroke. Two other outlying 
results from relatively small studies were attributed to random 
variation (103, 111).
Attempts to use the AHA/ASA proposals highlight the vital 
importance of always providing complete definitions of stroke 
and TIA, particularly definitions that are unambiguous and uni-
versally applicable (at least at a fundamental level). Moreover, 
attempts to use the AHA/ASA proposals force incompatibility 
with all past measurements of stroke and TIA rate (101). In this 
instance, the documentation of a continuing fall in the risk of 
ipsilateral stroke in patients with asymptomatic carotid stenosis 
given medical treatment alone (lifestyle coaching and medica-
tion) was almost lost because of attempts to use the AHA/ASA 
proposals. This kind of significant problem is avoidable if we 
continue to record the persistence, or not, of clinical deficits 
beyond 24 h (a practical time-point) (20, 100) and sub-classify 
patients according to this timing and, where appropriate, then 
according to the neuroimaging findings.
tHe proposaLs are otHerWise 
CLiniCaLLy UnHeLpFUL
Limitations imposed by access  
to neuroimaging
The proposed definitions are constrained by access to acute state-
of-the-art brain imaging, specialized acute stroke services and 
patient compatibility with certain imaging techniques. Stroke and 
imaging services are most available in high-income countries 
and, even there, access is variable (99, 114). Further, approxi-
mately 70% of strokes world-wide occur in low-middle income 
countries (115). Hence, the proposed imaging-dominant defini-
tions would be applicable to a very biased selection of patients. 
To define all stroke and TIA by a subcategory of imaged patients is 
inappropriate. By contrast, the established clinically based defini-
tions are accessible to all patients because they are dependent only 
on clinical status with sub-classification as resources allow.
FiGUre 1 | Continued fall in the rate of ipsilateral stroke in patients with >50% 
carotid stenosis given medical treatment alone since 2007. Sixty-seven percent 
relative (or 1.7% absolute) fall in the reported average annual ipsilateral stroke rate 
in patients with >50% ACS given medical intervention alone from 1985 to 2013. 
Black diamonds are study results with corresponding sample sizes. As in 2009, 
the Ryan-Holm stepdown Bonferroni correction was made for multiple 
comparisons (converting raw P values to P′ values, SYSTAT 13, SYSTAT Software 
Inc.) (3). UPL and LPL, respectively, upper and lower 95% prediction limits for new 
population rate estimates; UCL and LCL (dashed lines), respectively = upper and 
lower 95% confidence limits for the population regression line; WRL, weighted 
regression line; ACAS, Asymptomatic Carotid Atherosclerosis Study (112); 
CREST1, Carotid Revascularization Endarterectomy versus Stenting Trial (113). ** 
indicates two studies including a small minority with remote ipsilateral stroke/
transient ischemic attack at baseline (17, 108). These were included in this analysis 
because the regression line was not very different with (y = 2.861 – 0.061x, P′ for 
slope and y intercept <0.00000 and r2 = 0.379) or without them (y = 2.720 – 
0.051 x, P′ for slope and y intercept <0.00000 and r2 = 0.275). Both analyses 
showed a statistically significant fall in stroke risk from 1985 to 2013 although it 
was a little less in magnitude when the studies by Markus et al. (17) and Madani et 
al. (108) were excluded (57% relative and 1.4% absolute fall in rate). The outlier 
result (white diamond) (106) was not included in these analyses (see text). 
Abbreviations: CEA, carotid endarterectomy; CAS, carotid stenting.
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negative patient psycho-social 
implications
The negative psycho-social implications of the proposals need 
to be considered. With a growing focus on imaging alone to 
diagnose stroke, we are seeing more patients in clinical practice 
with non-specific symptoms and non-specific imaging findings 
being diagnosed with stroke when this is not justified. Further, 
patients who would have previously been diagnosed with TIA are 
now being diagnosed with stroke because of imaging findings. 
Stroke, in contrast to TIA, implies the likelihood of persisting 
deficits. Persons diagnosed with stroke are expected to inform 
other clinicians, licensing authorities, insurance companies, 
potential employers, and others of their diagnosis. They are likely 
to be unfairly restricted if the diagnosis is inaccurate relative 
to the established clinically based definitions upon which the 
evidence base is derived. Such over-diagnosis of stroke is likely 
to cause avoidable anxiety (116) and exposure to unnecessary 
stroke prevention treatments which carry risk and financial cost 
without benefit.
encouragement of over- and  
Under-treatment
Over-treatment is likely to be compounded by the AHA/ASA 
proposed lumping together of asymptomatic and symptomatic 
patients with brain imaging findings under a diagnosis of stroke. 
As already discussed, imaging can only ever provide evidence 
of infarction. MRI evidence of brain lesions, commonly referred 
to as “infarction,” in asymptomatic people becomes increasingly 
common with age and is also highly dependent on reporting 
methods (36, 117). Further, the asymptomatic and symptomatic 
states should be distinguished as clearly as possible because they 
differ so much with respect to prognosis and potential gain 
from intervention (118). Under-treatment is also encouraged 
by the proposals. “Imaging-negative” TIA or stroke patients 
(without “positive” neuroimaging evidence of ischemia) may 
not be recognized as likely to benefit from treatment. They risk 
being denied proven therapies according to a large evidence 
base established using clinically based definitions and that was 
not reliant on detecting “positive” neuroimaging evidence of 
ischemia (5, 6, 51, 119).
tHe proposaLs do not soLVe  
tHe CHaLLenGes oF deLiVerinG 
HyperaCUte stroKe tHerapy
reasons Given to Change to  
imaging-dominant definitions
Reasons given for the AHA/ASA proposals relate to the chal-
lenges of administering hyperacute ischemic stroke therapy and 
are listed below:
 i. The 24-h symptom duration misclassifies up to one-third of 
patients who have experienced tissue infarction as not hav-
ing tissue infarction (19).
 ii. TIA is not seen as urgent (18).
 iii. A 24-h limit for transient cerebral ischemia is arbitrary 
and not reflective of the typical TIA duration (usually 
<30–60 mins) (18).
 iv. A 24-h differentiation has the potential to delay effective 
hyperacute stroke therapies (18, 19).
 v. There is no biological justification to continue to treat the 
24-h time-point as particularly helpful to recognize (19).
 vi. Physicians need to focus on the cause of ischemia rather than 
duration of symptoms (18, 19).
 vii. A “tissue-based” definition of TIA encourages use of neuro-
diagnostic tests (19).
How these issues should Be addressed
These perceived challenges will not be addressed by changing 
to imaging-dominant definitions of stroke and TIA. For the 
reasons already given, neuroimaging is unreliable for identifying 
histological infarction or for providing a “tissue-based” diagnosis. 
Neuroimaging provides a radiologically based diagnosis (or, 
more accurately, a radiologically based part of the diagnosis). 
Rather, the best approach is similar to non-invasively diagnosing 
acute myocardial infarction (also a pathologically defined tissue 
state). Here, clinical features, electrocardiographic changes, and 
cardiac enzyme levels, which are limited individually, have addi-
tive diagnostic value (120).
In particular, most patients (about 65%) with clinical features 
of acute focal brain ischemia lasting <24 h have no correspond-
ing DWI or other imaging evidence of ischemia (99). DWI 
findings in patients with acute clinical features of brain ischemia 
are more likely with increasing deficit duration and severity and 
other clinical and pathophysiological markers of poorer outcome 
(55, 78, 121, 122). We acknowledge reports that DWI-positive 
patients (including particularly those with clinical deficits last-
ing less than 24 h) have a poorer outcome than DWI-negative 
patients (55, 78, 121, 122). However, imaging results must be 
shown to independently predict outcome, despite all other 
predictive clinical and pathophysiological markers. Moreover, 
even if ‘positive’ imaging evidence of ischaemia (or the nature of 
it) (123) proves to be such an independent predictor, treatment 
decisions are not currently altered (51). Even if patient outcomes 
are somehow shown to improve by using advanced imaging 
techniques and detecting “positive” evidence of ischemia, cost-
effectiveness must be measured (119). Further, changes in defini-
tion of stroke and TIA will not necessarily be required to exploit 
such knowledge. Moreover, “imaging-positive” patients are likely 
to remain a subset of patients with acute central-neurovascular 
syndromes. Therefore, it is important to maintain the clinical 
focus and subcategorize according to available neuroimaging 
results.
There is no reason why the established clinically based 
definitions of stroke and TIA should cause complacency or 
delay appropriate therapy. Such problems are best addressed by 
education. The public and clinicians should be educated that 
to optimize patient outcomes, hyperacute therapies (such as 
thrombolysis and/or clot evacuation) should be administered 
as soon as possible within the first 4–6  h of clinical onset 
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FiGUre 2 | diagnostic and classification framework for syndromes due to focal, intrinsic, central-neurovascular compromise*,**,#.
(Continued)
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FiGUre 2 | Continued  
*These are the sequential layers of information that should be specified as far as possible when describing syndromes due to focal, intrinsic central-neurovascular 
compromise. These are syndromes referable to intrinsic disorders of particular blood vessels supporting the brain, retina, or spinal cord. This classification may be 
expanded when there is reason. As far as possible, qualifying terms such as “likely” or “confirmed” should be included to improve clarity.  
**This framework recognizes that the presence of a condition does not always mean causation (124). The mechanism of stroke or transient ischemic attack (TIA) in 
an individual is always about assigning probabilities (0–100%). Therefore, it is more accurate to speak of risk factors and their likeliness of contributing causation.  
#This is a classification of clinical syndromes (symptoms and/or signs). Asymptomatic neuroimaging findings should be classified separately and according to 
whether or not pathological characterization has occurred. Pathologically unconfirmed asymptomatic neuroimaging findings, such as suspected asymptomatic 
infarcts, should be classified as such with the reasons for suspecting a particular pathology. Asymptomatic neuroimaging findings can be sub-classified using the 
same principles as presented in Figure 2 where relevant, when known and when there is purpose.  
+The most commonly recognized “characteristic” “focal” clinical deficits associated with stroke and TIA include sudden facial weakness, weakness or incoordination 
involving one or more limbs, dysphasia, dysarthria, visual impairment, vestibular or cranial nerve dysfunction which are manifested according to the particular 
vascular territory involved and neural tissue being secondarily compromised (7, 12, 13, 15).  
++For computed tomography, these include hypo-attenuation relative to “normal” areas, loss of white/gray matter differentiation, focal cortical swelling, hyper-dense 
arterial signs, and/or compression of adjacent structures (25, 26). For magnetic resonance imaging these include diffusion-weighted, T2, and fluid attenuation 
inversion recovery hyperintensity (26, 39, 46).  
^TIA is rapidly developed clinical symptoms and/or signs of cerebral, retinal, or spinal cord dysfunction lasting <24 h, with no apparent cause other than of focal 
neurovascular origin where resolution is swift and leaves no detectable permanent neurologic deficit. It is recognized that transient ischemic attacks commonly last 
2–15 min. Adapted from the National Institutes of Health 1975 publication (12).  
^^Stroke is rapidly developed clinical symptoms and/or signs of cerebral, retinal, or spinal cord dysfunction lasting >24 h or leading to death, with no apparent cause 
other than of focal neurovascular origin. It is recognized that the deficits typically appear suddenly but may progress or fluctuate (not resolving), particularly over 
minutes to hours after onset. Adapted from Aho et al. (7).  
^^^Infarction is a pathological term used to describe tissue that has lost its blood supply for long enough to undergo ischemic necrosis (death) with characteristic 
macroscopic and microscopic findings (21).  
##Severity may be measured according to meaningful scales such as the modified Rankin (for activities of daily living) (125). “Fully resolved, mild, moderate, severe, 
or fatal” should be used in preference to “disabling” versus “non-disabling” to describe severity because even mild strokes are associated with disability unless all 
measurable deficits have resolved.
(5, 6). This is because imaging evidence of brain damage and 
the likelihood of a permanent deficit is seen in proportion to 
the duration of the deficit. Further, it should be acknowledged 
that in trials of thrombolysis and clot evacuation it was likely 
that some patients would have improved spontaneously and this 
was not predictable. However, overall, patients were better with 
treatment. It needs to be communicated that the aim in trials 
and clinical practice is to improve overall chances of converting 
long-term deficits (strokes) into transient ones (TIAs) and severe 
deficits into milder ones. Therefore, delaying transfer to hospital 
or hyperacute therapy to see if a deficit resolves is not justified. 
Further, the established definitions do not need to hinder patho-
physiological work up.
Finally, at least one universally standardized time-point is 
required to differentiate short-lived, fully resolved clinical deficits 
from long-term ones, whether or not there has been any infarction 
or hyperacute therapy. As already explained, there is great clinical 
value in continuing this. There is no compelling data showing that 
an alternative time threshold is superior to, or more useful than 
24 h (20). Further, the shorter the time-point used to differenti-
ate stroke (long-term deficits) from TIA (short-term deficits) the 
harder it is to administer treatment to abort “stroke.” Anything 
less than 24 h will still be subject to the problems of being sure 
about how much tissue infarction has occurred. Moreover, the 
deficit duration and severity are more important than proving 
the presence or not of infarction and should remain the primary 
targets of treatment strategies. The 24-h time-point should be 
retained because it predominates in past research and is practical 
and useful to measure, whether or not patients are admitted to 
hospital or they receive hyperacute therapy. Additional times may 
be documented where there is reason.
ConCLUsion and tHe Way ForWard
the importance of Clinically Based 
definitions
In conclusion, the patient’s clinical status (nature and dura-
tion of deficits) needs to remain the basis of stroke and TIA 
definitions because this is what matters most and has been the 
main outcome of prognostic and therapeutic studies. Further, 
definitions focused on the clinical deficit allow inclusion of all 
affected persons, reduce the risk of mis-diagnosis, and encour-
age continued collection of data regarding asymptomatic as 
distinct from symptomatic patients, and typical stroke and TIA 
patients as distinct from other presentations which may have 
different causation. Simplified clinical assessment and imaging 
interpretation cannot replace assessment by a stroke specialist 
(119). The value of a highly experienced expert physician is 
priceless and should be more highly valued by the profession as 
well as by patients.
The duration of the clinical deficit with respect to lasting more 
or less than 24 h should still always be recorded so that brief resolv-
ing deficits can be systematically distinguished from lasting ones, 
whether or not hyperacute stroke therapies are administered. TIA 
and stroke, respectively, define outcomes up to and beyond 24 h 
of clinical onset. Therefore, they are used retrospectively. Terms 
like “acute central-neurovascular syndrome” (19) or “threatening 
stroke” may help with communication during the first 24  h of 
clinical onset. However, patients fundamentally want to know if 
they have a stroke-related deficit and the likelihood that treat-
ment may help resolve or minimize it.
Brain imaging remains a critical tool to characterize and 
sub-classify clinically defined stroke and TIA patients and help 
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determine appropriate therapy. It is a significant advance that 
modern neuroimaging is now more likely to provide positive 
evidence of neural ischemia or infarction rather than to only help 
exclude other pathological processes, such as bleeding. However, 
the limitations of neuroimaging (especially if used as the pre-
dominant or only source of information) must be kept in mind. 
Further, infarction should remain a pathological term, allowing 
recognition that it is not reliably identified by neuroimaging and 
that accurate identification of infarction is not usually required 
to optimize patient outcomes. Challenges regarding the new era 
of hyperacute stroke therapy are best faced through appropriate 
education and resource organization. The AHA/ASA proposals 
to merge the established clinically based definitions of stroke and 
TIA with each other and with pathologically defined infarction 
according to “positive” imaging findings must not be accepted. 
The AHA/ASA proposed new “definitions” are ambiguous, 
scientifically incorrect, research disrupting, otherwise clinically 
unhelpful, and do not solve the problems they were proposed to 
solve.
improving the Use of Clinically  
Based definitions
Research, and its application in clinical practice, requires standard 
definitions, and these need to be scientifically valid and optimized 
with respect to clinical relevance. Although the established 
clinically based definitions of stroke and TIA provide the best 
foundation (using sub-classification according to the available 
results from imaging and/or other investigations), use of these 
terms should be improved by:
 i. providing detail about typical clinical presentations and if/
how stroke mimics were distinguished (34, 119).
 ii. specifying the inclusion, or not, of stroke and TIA of the 
retina, brain and/or spinal cord and
 iii. specifying as clearly as possible the inclusion, or not, of 
syndromes due to arterial and/or venous infarction or hemor-
rhage (20).
In addition, it should not be forgotten that episodes of apparent 
global dysfunction (such as impaired consciousness) may occasion-
ally be caused by ischemic or haemorrhagic compromise directly 
referable to one or more cerebral artery (8–11). A summary of 
these and other proposed improvements for using the established 
clinically based definitions of stroke and TIA is given in Figure 2. 
This framework is universally accessible at the most fundamental 
levels and, at the same time, can be used as we advance further into 
“personalized” (more individually tailored) medicine.
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